These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model. Steinbeck JA; Choi SJ; Mrejeru A; Ganat Y; Deisseroth K; Sulzer D; Mosharov EV; Studer L Nat Biotechnol; 2015 Feb; 33(2):204-9. PubMed ID: 25580598 [TBL] [Abstract][Full Text] [Related]
3. Stem cell therapies for Parkinson's disease: are trials just around the corner? Drouin-Ouellet J; Barker RA Regen Med; 2014; 9(5):553-5. PubMed ID: 25372072 [No Abstract] [Full Text] [Related]
8. The bioengineering of stem cells to create dopamine replacement neurons is not the solution for Parkinson's. Carey RJ; Carey JL Pharmacol Biochem Behav; 2017 Dec; 163():36-37. PubMed ID: 29066358 [No Abstract] [Full Text] [Related]
9. [Cell therapy for Parkinson's disease: III. Neonatal, fetal and embryonic stem cell-based applications]. Anisimov SV Adv Gerontol; 2009; 22(2):296-315. PubMed ID: 19947394 [TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease: fetal cell or stem cell derived treatments. Astradsson A; Aziz T BMJ; 2016 Jan; 352():h6340. PubMed ID: 26743154 [No Abstract] [Full Text] [Related]
12. Optogenetic neuromodulation. Kalanithi PS; Henderson JM Int Rev Neurobiol; 2012; 107():185-205. PubMed ID: 23206683 [TBL] [Abstract][Full Text] [Related]
13. A well-refined in vitro model derived from human embryonic stem cell for screening phytochemicals with midbrain dopaminergic differentiation-boosting potential for improving Parkinson's disease. Hsieh WT; Chiang BH J Agric Food Chem; 2014 Jul; 62(27):6326-36. PubMed ID: 24933592 [TBL] [Abstract][Full Text] [Related]
14. Fetal grafts for Parkinson's disease: Decades in the making. Kordower JH; Olanow CW Proc Natl Acad Sci U S A; 2016 Jun; 113(23):6332-4. PubMed ID: 27247420 [No Abstract] [Full Text] [Related]
15. Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: current state and problems. Hwang DY; Kim DS; Kim DW J Cell Biochem; 2010 Feb; 109(2):292-301. PubMed ID: 20014069 [TBL] [Abstract][Full Text] [Related]
16. [Cell replacement therapy with human ES cells for the treatment of Parkinson's disease]. Takahashi J No Shinkei Geka; 2007 Sep; 35(9):935-43. PubMed ID: 17867315 [No Abstract] [Full Text] [Related]
17. What is the most promising treatment for Parkinson's disease: genes, cells, growth factors or none of the above? Cummins G; Barker RA Regen Med; 2012 Sep; 7(5):617-21. PubMed ID: 22954429 [No Abstract] [Full Text] [Related]
19. Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era. Barker RA; Parmar M; Studer L; Takahashi J Cell Stem Cell; 2017 Nov; 21(5):569-573. PubMed ID: 29100010 [TBL] [Abstract][Full Text] [Related]
20. Human cord blood-derived multipotent stem cells (CB-SCs) treated with all-trans-retinoic acid (ATRA) give rise to dopamine neurons. Li X; Li H; Bi J; Chen Y; Jain S; Zhao Y Biochem Biophys Res Commun; 2012 Mar; 419(1):110-6. PubMed ID: 22330803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]